Encorafenib + Cetuximab + Oxaliplatin + Irinotecan + Leucovorin + 5-FU + Capecitabine + Bevacizumab

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Neoplasms

Conditions

Neoplasms

Trial Timeline

Dec 21, 2020 → Dec 28, 2027

NCT ID

NCT04607421

About Encorafenib + Cetuximab + Oxaliplatin + Irinotecan + Leucovorin + 5-FU + Capecitabine + Bevacizumab

Encorafenib + Cetuximab + Oxaliplatin + Irinotecan + Leucovorin + 5-FU + Capecitabine + Bevacizumab is a phase 3 stage product being developed by Ono Pharmaceutical for Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT04607421. Target conditions include Neoplasms.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasms were approved

Approved (20) Terminated (2) Active (0)

✅LenvatinibEisaiApproved

✅Eribulin mesylateEisaiApproved

✅Eribulin MesylateEisaiApproved

✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved

✅Chlorhydrate de RopivacaineAstraZenecaApproved

✅Sitagliptin + placeboMerckApproved

✅Palonosetron and DexamethasoneMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04607421	Phase 3	Active	Dec 21, 2020	Dec 28, 2027	Neoplasms

Competing Products

20 competing products in Neoplasms

See all competitors

Product	Company	Stage	Hype Score
ADC-1013	Alligator Bioscience AB	Phase 1	19
AB0024	Gilead Sciences	Phase 1	29
TTI-237	Pfizer	Phase 1	21
852A	Pfizer	Phase 1	29
Pemetrexed	Eli Lilly	Phase 2	35
IMC-3C5	Eli Lilly	Phase 1	29
LY3295668	Eli Lilly	Phase 1/2	32
Galunisertib + Gemcitabine + Placebo	Eli Lilly	Phase 1/2	32
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	39
Abemaciclib + Fulvestrant + Placebo	Eli Lilly	Phase 3	44
LY2784544	Eli Lilly	Phase 1	29
enzastaurin	Eli Lilly	Phase 2	35
Abemaciclib + Darolutamide + LHRH agonist/antagonist	Eli Lilly	Phase 1	29
Gemcitabine + liposomal doxorubicin	Eli Lilly	Phase 3	40
120 mg LY2784544	Eli Lilly	Phase 2	39
LY4337713	Eli Lilly	Phase 1	36
pemetrexed + cisplatin	Eli Lilly	Phase 1/2	32
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant	Eli Lilly	Phase 3	47
VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg	Vincerx Pharma	Phase 1	19
VIP236 (Q3W) + VIP236 (Q2W)	Vincerx Pharma	Phase 1	19